Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WGc-043
- Development stage
- Phase 1
- Lead developer
- Chengdu Weisijin Biopharmaceutical Technology
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
WGc-043 is a therapeutic mRNA cancer vaccine developed by WestGene Biopharma. It targets Epstein-Barr virus (EBV)-associated malignancies, including both solid tumors and hematologic cancers such as extranodal NK/T-cell lymphoma (ENKTL) and nasopharyngeal carcinoma. The vaccine utilizes AI-assisted antigen screening to identify optimal EBV-related targets and is delivered via a proprietary lipid nanoparticle (LNP) system. WGc-043 is designed to induce a potent anti-tumor immune response by presenting EBV-specific antigens to the immune system. It has received Investigational New Drug (IND) approvals from both the U.S. FDA and China's NMPA, marking a significant milestone as a dual-approved mRNA vaccine for EBV-related cancers.
- Other names
- EBV mRNA vaccine
02
Targets
Epstein-Barr virus antigens/proteins
Beyond the preview
Go deeper on WGc-043.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WGc-043.